新闻源 财富源

2019年10月14日 星期一

誉衡药业(002437)公告正文

誉衡药业:2013年第一季度报告正文

公告日期:2013-04-26

                                  哈尔滨誉衡药业股份有限公司 2013 年第一季度报告正文
    证券代码:002437   证券简称:誉衡药业            公告编号:2013-027哈尔滨誉衡药业股份有限公司 2013 年第一季度报告正文
                                                   哈尔滨誉衡药业股份有限公司 2013 年第一季度报告正文
                                  第一节 重要提示
    公司董事会、监事会及董事、监事、高级管理人员应当保证季度报告内容的真实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。
    公司负责人朱吉满、主管会计工作负责人杨华蓉及会计机构负责人(会计主管人员)宋宇冰声明:保证季度报告中财务报表的真实、准确、完整。
    所有董事均已出席了审议本次季报的董事会会议。
                                                               哈尔滨誉衡药业股份有限公司 2013 年第一季度报告正文
                            第二节 主要财务数据及股东变化一、主要财务数据本报告期对以前期间财务数据是否进行了追溯调整或重述□ 是 √ 否
                                                                                              本报告期比上年同期增减
                                         2013 年 1-3 月              2012 年 1-3 月
                                                                                                      (%)
    营业收入(元)                                208,359,093.85               126,631,366.65                      64.54%
    归属于上市公司股东的净利润(元)               19,949,918.38                17,227,050.07                      15.81%归属于上市公司股东的扣除非经常性损
                                               15,503,823.34                13,783,014.88                      12.48%益的净利润(元)
    经营活动产生的现金流量净额(元)               35,173,744.14                24,646,265.78                      42.71%
    基本每股收益(元/股)                                       0.07                       0.06                    16.67%
    稀释每股收益(元/股)                                       0.07                       0.06                    16.67%
    加权平均净资产收益率(%)                                 0.85%                       0.79%                     0.06%
                                                                                              本报告期末比上年度期末
                                       2013 年 3 月 31 日          2012 年 12 月 31 日
                                                                                                     增减(%)
    总资产(元)                                 2,712,747,378.14            2,564,606,116.90                       5.78%
    归属于上市公司股东的净资产(元)             2,352,332,440.55            2,332,860,682.13                       0.83%非经常性损益项目和金额√ 适用 □ 不适用
                                                                                                               单位:元
                         项目                               年初至报告期期末金额                    说明
    非流动资产处置损益(包括已计提资产减值准备的冲销部分)                        810.00
    除上述各项之外的其他营业外收入和支出                                      -29,300.34
    其他符合非经常性损益定义的损益项目                                      5,259,191.03
    所得税影响额                                                              784,605.65
    合计                                                                    4,446,095.04                  --二、报告期末股东总数及前十名股东持股情况表
                                                                                                               单位:股
    报告期末股东总数                                                                                                12,592
                                           前 10 名股东持股情况
                                                              哈尔滨誉衡药业股份有限公司 2013 年第一季度报告正文
                                                                   持有有限售条件         质押或冻结情况
    股东名称       股东性质      持股比例(%)    持股数量
                                                                     的股份数量       股份状态          数量哈尔滨恒世达昌
                 境内非国有法人          44.63%      124,950,000       124,950,000 质押                 60,000,000科技有限公司YU HENGINTERNATION
    AL               境外法人                   21%       58,800,000        58,800,000INVESTMENTSCORPORATIONORIENTALKEYSTONE
                 境外法人                  2.5%        6,997,085                  0INVESTMENTLIMITED中国建设银行-华夏红利混合型
                 其他                     1.89%        5,299,909                  0开放式证券投资基金中国工商银行-
    博时精选股票证 其他                       1.43%        4,000,000                  0券投资基金中国银行-银华
    优质增长股票型 其他                       1.25%        3,500,000                  0证券投资基金全国社保基金一
                 其他                     0.86%        2,399,496                  0一八组合全国社保基金四
                 其他                     0.74%        2,060,799                  0一八组合中国建设银行-
    华夏收入股票型 其他                       0.56%        1,570,224                  0证券投资基金中国银行-华夏策略精选灵活配
                 其他                     0.55%        1,549,919                  0置混合型证券投资基金
                                         前 10 名无限售条件股东持股情况
                                                                                             股份种类
             股东名称                       持有无限售条件股份数量
                                                                                      股份种类          数量ORIENTAL KEYSTONE
                                                                         6,997,085 人民币普通股          6,997,085INVESTMENT LIMITED
                                                           哈尔滨誉衡药业股份有限公司 2013 年第一季度报告正文中国建设银行-华夏红利混合型
                                                                     5,299,909 人民币普通股        5,299,909开放式证券投资基金中国工商银行-博时精选股票证
                                                                     4,000,000 人民币普通股        4,000,000券投资基金中国银行-银华优质增长股票型
                                                                     3,500,000 人民币普通股        3,500,000证券投资基金
    全国社保基金一一八组合                                               2,399,496 人民币普通股        2,399,496
    全国社保基金四一八组合                                               2,060,799 人民币普通股        2,060,799中国建设银行-华夏收入股票型
                                                                     1,570,224 人民币普通股        1,570,224证券投资基金中国银行-华夏策略精选灵活配
                                                                     1,549,919 人民币普通股        1,549,919置混合型证券投资基金中信证券-中信-中信证券股票
                                                                     1,395,496 人民币普通股        1,395,496精选集合资产管理计划中国农业银行-银华内需精选股票
                                                                     1,190,434 人民币普通股        1,190,434型证券投资基金
                                哈尔滨恒世达昌科技有限公司、YU HENG INTERNATIONAL INVESTMENTS
    上述股东关联关系或一致行动的    CORPORATION 以及 ORIENTAL KEYSTONE INVESTMENT LIMITED 属同一实际控
    说明                            制人控制,未知其他股东是否存在关联关系,也未知是否属于《上市公司持股变动信息
                                披露管理办法》中规定的一致行动人。
                                                                            哈尔滨誉衡药业股份有限公司 2013 年第一季度报告正文
                                                      第三节 重要事项
       一、报告期主要会计报表项目、财务指标发生重大变动的情况及原因
       1、资产负债表
       项目        期末金额        期初金额      变动金额      变动率    占资产总额                        原因说明
                                                                            比例
    货币资金           116,297.83      126,270.41      -9,972.57    -7.90%       42.87% 主要是本期购买交易性金融资产1.2亿
    交易性金融资产         20,000.00     8,000.00     12,000.00    150.00%        7.37% 本期购买交易性金融资产1.2亿
    应收票据                 269.75        504.48       -234.73    -46.53%        0.10% 应收票据到期结算
    应收账款                7,855.01     4,357.48      3,497.53     80.27%        2.90% 进一步扩大新销售模式实施范围
    预付款项               16,688.43    32,364.74     -15,676.32   -48.44%        6.15% 年初预付蒲公英增资款17250万元转为投资
    应收利息                 268.29        402.44       -134.15    -33.33%        0.10% 本年已收到部分计提的存款利息
    其他应收款              7,715.22    12,037.15      -4,321.93   -35.90%        2.84% 广州新花城收到上年末山东誉衡支付广州产权交易所收
                                                                                      购款3800万
    存货                    9,950.62     6,753.75      3,196.86     47.33%        3.67% 蒲公英纳入合并范围增加存货1343万;其他为销售增加,
                                                                                      相应增加的库存储备
    固定资产               46,456.33    43,426.08      3,030.25      6.98%       17.13% 蒲公英纳入合并范围增加固定资产2865万
    无形资产               24,502.80     6,201.53     18,301.27    295.11%        9.03% 蒲公英纳入合并范围增加无形资产18370万
    商誉                    7,726.50     3,417.00      4,309.50    126.12%        2.85% 收购蒲公英药业导致商誉增加
    长期待摊费用             555.38        828.86       -273.47    -32.99%        0.20% 待摊费用继续摊销导致总额减少
    递延所得税资产           795.43        598.02        197.41     33.01%        0.29% 合并范围内未实现毛利较期初增加所致
    应付账款                5,171.21     3,530.53      1,640.69     46.47%        1.91% 主要是应付采购货款增加
    预收款项                 433.60        192.13        241.47    125.68%        0.16% 主要是美迪预收项目款增加
    应付职工薪酬             212.10         82.12        129.98    158.28%        0.08% 已计提未支付的职工薪酬较期初增加
    其他应付款             16,907.28    11,947.25      4,960.03     41.52%        6.23% 蒲公英、西藏阳光纳入合并范围所致
    递延所得税负债             40.24        60.37         -20.12   -33.33%        0.01% 收到部分预提利息,因此相应递延所得税负债转回
    其他非流动负债           194.60        139.60         55.00     39.40%        0.07% 收到研发相关补贴款55万
       2、利润表
       项目            本期          上期        变动金额      变动率    占收入总额                        原因说明
                                                                            比例
    营业收入               20,835.91     12,663.14      8,172.77    64.54%       100.00% 蒲公英纳入合并范围、销售模式调整及销售份额增加三
                                                                                       方面因素影响所致
    营业成本                6,890.84      5,475.93      1,414.91    25.84%        33.07% 销售增加导致总成本增加
    营业税金及附加           300.25         109.84       190.42    173.36%         1.44% 销售增加所致
    销售费用                8,565.96      3,184.85      5,381.12   168.96%        41.11% 为增加销售,继续加大对市场的开发投入
    管理费用                2,933.96      2,148.45       785.51     36.56%        14.08% 蒲公英、西藏阳光纳入合并范围所致
                                                                             哈尔滨誉衡药业股份有限公司 2013 年第一季度报告正文
    财务费用                 -326.81      -590.75        263.95   -44.68%           -1.57% 资金规模下降,利息收入减少
    投资收益                 176.71          0.00        176.71   100.00%           -0.05% 本期取得理财收益,上年同期无
    所得税费用               571.23       632.06         -60.83      -9.62%           0.85% 主要是合并范围内未实现毛利较期初增加所致
      3、现金流量表
                 项目                      本期           上期         变动金额       变动率                         原因说明
    销售商品、提供劳务收到的现金               18,039.44     14,636.84         3,402.61    23.25% 销售回款增加
    收到其他与经营活动有关的现金                4,108.15      1,747.42         2,360.73   135.10% 主要是蒲公英、西藏阳光纳入合并范围增加
    支付的各项税费                              3,265.61      1,666.45         1,599.17    95.96% 销售增加税费增加
    支付其他与经营活动有关的现金                6,366.15      4,272.98         2,093.17    48.99% 销售费用增加所致
    收回投资收到的现金                         20,800.00          0.00        20,800.00   100.00% 收回理财投资支出
    取得投资收益收到的现金                          176.71        0.00          176.71    100.00% 取得理财投资收益
    收到其他与投资活动有关的现金                4,210.09          0.00         4,210.09   100.00% 主要为广州新花城收到上年末山东誉衡支付广
                                                                                                州产权交易所收购款3800万
    购建固定资产、无形资产和其他长期资产        6,171.57      4,125.01         2,046.56    49.61% 主要是在建募投项目支出较上年增加支付的现金
    投资支付的现金                             32,800.00          0.00        32,800.00   100.00% 理财投资支出
    收到其他与筹资活动有关的现金                    349.33    2,520.40        -2,171.07   -86.14% 上年同期收到1年定期存款利息2425万所致
    分配股利、利润或偿付利息支付的现金               54.47        0.00           54.47    100.00% 本年支付长期借款利息
      二、重要事项进展情况及其影响和解决方案的分析说明
      1、本公司于2012年10月27日与刘丽颖、贾德君及哈尔滨蒲公英药业有限公司(以下简称“蒲公英药业”)签订了关于蒲公
      英药业增资扩股协议,本公司首期支付增资款17,250万元取得蒲公英药业75%股权。蒲公英药业的主要产品(即安脑丸和安
      脑片)已于2013年3月16日进入现行国家基本药物目录,根据协议规定,本公司需另行支付增资款3,750万元。合计总投资
      21,000万。2013年1月6 日正式办理蒲公英药业经营权转移手续,工商变更登记手续于2013年3月7日办理完毕。蒲公英已纳
      入1季度合并范围,本报告期末资产总额25,578万,本期实现营业收入1,013.63万,净利润97.73万。
      2、公司于2013年3月14日召开了二届十四次董事会,同意公司拟使用部分超额募集资金人民币42,000万元用于收购澳诺(中
      国)制药有限公司100%股权;目前正在办理相关部门的审批手续。
                     重要事项概述                                披露日期                           临时报告披露网站查询索引
       部分超额募集资金使用计划(2012 年 12
                                                 2012 年 12 月 13 日                           2012-074
       月)(对蒲公英药业进行增资扩股)
       部分超额募集资金使用计划(2013 年 3
                                                 2013 年 03 月 18 日                           2013-014
       月)(收购澳诺(中国)股权)
      三、公司或持股 5%以上股东在报告期内或持续到报告期内的承诺事项
                        承诺事项                     承诺方            承诺内容        承诺时间           承诺期限        履行情况
                                                             哈尔滨誉衡药业股份有限公司 2013 年第一季度报告正文股改承诺
                                                    承诺所持有的
                                                    公司股份自本
    收购报告书或权益变动报告书中所作承 恒世达昌、誉衡 权益变动报告        2013 年 02 月 08
                                                                                         12 个月   履行中
    诺                                 国际、健康科技 书签署之日起        日
                                                    12 个月内不予
                                                    减持。资产重组时所作承诺
                                                    自公司股票上
                                                    市之日起三十
                                                    六个月内,不转
                                   恒世达昌、誉衡 让或者委托他
                                                                      2010 年 06 月 23
    首次公开发行或再融资时所作承诺     国际以及百庚     人管理其持有                         36 个月   履行中
                                                                      日
                                   禹丰             的发行人股份,
                                                    也不由发行人
                                                    回购其持有的
                                                    股份。
                                                    自公司股票在
                                                    证券交易所上
                                                    市之日起三十
                                                    六个月内,不转
                                                    让或者委托他
                                                    人管理其持有
                                                    恒世达昌和誉
                                                    衡国际的股份,
                                                    也不由恒世达
                                                    昌和誉衡国际
                                   朱吉满和白莉
                                                    回购该部分股
                                   惠夫妇、王东绪                     2010 年 06 月 23
                                                    份;在上述承诺                                 履行中
                                   先生、杨红冰先                     日
                                                    的限售期届满
                                   生
                                                    后,在担任公司
                                                    董事、监事或高
                                                    管人员期间,每
                                                    年转让的股份
                                                    不超过所间接
                                                    持有公司股份
                                                    总数的 25%;离
                                                    职后半年内,不
                                                    转让所间接持
                                                    有的公司股份。
                                                    承诺如果公司
                                   恒世达昌以及                       2010 年 06 月 23
                                                    2005 年度、2006                                履行中
                                   朱吉满和白莉                       日
                                                    年度按照高新
                       哈尔滨誉衡药业股份有限公司 2013 年第一季度报告正文
    惠夫妇         技术企业税收
               优惠政策所享
               受的减按 15%
               的税率征收企
               业所得税的税
               收优惠被认定
               无效,本公司需
               要补缴税金、滞
               纳金、罚金或承
               担其它赔偿责
               任的,将由恒世
               达昌以及朱吉
               满和白莉惠夫
               妇向本公司予
               以全额补偿,并
               承担连带责任。
               承诺其及其实
               际控制的企业
               或单位(“附属公
               司”)目前并没有
               直接或间接地
               从事任何与公
               司实际从事的
               业务发生利益
               冲突或在市场、
               资源、地域方面
               存在竞争的任
               何业务活动。其
               及其附属公司
    朱吉满和白莉   在今后的任何      2010 年 06 月 23
                                                          履行中
    惠夫妇         时间不会直接      日
               或间接地以任
               何方式(包括但
               不限于自营、合
               资或联营)参与
               或进行与公司
               实际从事的业
               务存在直接或
               间接竞争的任
               何业务活动(与
               公司合作开发
               除外)。其及其
               附属公司有任
               何商业机会可
                    哈尔滨誉衡药业股份有限公司 2013 年第一季度报告正文
           从事、参与或入
           股任何可能会
           与公司生产经
           营构成竞争的
           业务,会将上述
           商业机会优先
           让予公司。
           承诺其持有权
           益达 50%以上
           或实际控制的
           企业或单位(“附
           属公司”)目前并
           没有直接或间
           接地从事任何
           与公司实际从
           事的业务发生
           利益冲突或在
           市场、资源、地
           域方面存在竞
           争的任何业务
           活动。其及其附
           属公司在今后
           的任何时间不
           会直接或间接
           地以任何方式
                             2010 年 06 月 23
    恒世达昌   (包括但不限于                               履行中
                             日
           自营、合资或联
           营)参与或进行
           与公司实际从
           事的业务存在
           直接或间接竞
           争的任何业务
           活动(与公司合
           作开发除外)。
           凡其及其附属
           公司有任何商
           业机会可从事、
           参与或入股任
           何可能会与公
           司生产经营构
           成竞争的业务,
           会将上述商业
           机会优先让予
           公司。
                                                                           哈尔滨誉衡药业股份有限公司 2013 年第一季度报告正文其他对公司中小股东所作承诺
    承诺是否及时履行                            是
    未完成履行的具体原因及下一步计划            不适用是否就导致的同业竞争和关联交易问题
                                            是作出承诺
    承诺的解决期限                              不适用
    解决方式                                    不适用
    承诺的履行情况                              不适用四、对 2013 年 1-6 月经营业绩的预计2013 年 1-6 月预计的经营业绩情况:归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形2013 年 1-6 月归属于上市公司股东的净利润变
                                                                                                0%       至                                50%动幅度(%)2013 年 1-6 月归属于上市公司股东的净利润变
                                                                                         7,785.34        至                           11,678动区间(万元)2012 年 1-6 月归属于上市公司股东的净利润(万
                                                                                                                                     7,785.34元)
                                                        公司继续加大重点产品的市场开拓力度,加强管理,控制费用,稳步提高业绩变动的原因说明
                                                        企业盈利能力。五、上市公司发生控股股东及其关联方非经营性占用资金情况
                                                            报告期新增 报告期偿还
    股东或关                                期初数(万                                      期末数(万 预计偿还方 预计偿还金 预计偿还时
            占用时间     发生原因                            占用金额 总金额(万
    联人名称                                   元)                                            元)              式   额(万元) 间(月份)
                                                             (万元)     元)
    合计                                                    0             0              0               0        --                0     --
    期末合计值占期末净资产的比例(%)                                                                                                             0%六、证券投资情况
                             最初投资 期初持股 期初持股 期末持股 期末持股 期末账面 报告期损 会计核算
    证券品种 证券代码 证券简称                                                                                                          股份来源
                             成本(元)数量(股)比例(%)数量(股)比例(%)值(元) 益(元)                            科目
    期末持有的其他证券投资               0.00                   0    --              0         --             0.00     0.00    --          --
    报告期已出售证券投资损益            --             --            --       --               --            --        0.00    --          --
    合计                                 0.00                   0    --              0         --             0.00     0.00    --          --持有其他上市公司股权情况的说明无哈尔滨誉衡药业股份有限公司 2013 年第一季度报告正文
                       哈尔滨誉衡药业股份有限公司
                          法定代表人:朱吉满 先生
                           二〇一三年四月二十六日